Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,662 across all filing types
Latest filing 2025-03-03 Regulatory Filings
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Regulatory Filings Classification · 99% confidence The document is a press release dated March 3, 2025, announcing that Valneva's senior management will participate in upcoming investor conferences (TD Cowen and Van Lanschot Kempen). It details the dates, locations, and the topics management will discuss (pipeline, marketed vaccines, revenue guidance). This type of announcement, which informs investors about management's schedule for meetings and presentations at third-party industry events, is typically classified as an Investor Presentation or related communication, but none of the specific codes fit perfectly for a mere *announcement* of participation in external conferences. However, the content is highly focused on investor relations, pipeline updates, and financial outlook, which aligns closely with the purpose of an Investor Presentation (IP) or a general announcement. Since it is not a formal regulatory filing (like 10-K, IR, ER), nor a specific transaction notice (DIV, SHA, POS), and it is not a transcript (CT), the closest fit among the options that deals with management communicating strategy and financials to investors is Investor Presentation (IP). It is not an RPA because it is not announcing the publication of a formal report, but rather management's schedule.
2025-03-03 English
6-K
Regulatory Filings
2025-02-28 English
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
Earnings Release Classification · 99% confidence The document is a press release dated February 28, 2025, announcing that Valneva received a positive opinion from the EMA's CHMP regarding a label extension for its vaccine IXCHIQ®. This type of announcement, detailing regulatory milestones, clinical data updates, and strategic partnerships (like those with CEPI and SII), is characteristic of an Earnings Release (ER) or a general press release regarding corporate/product development. Since it focuses on key financial/product news rather than being a full quarterly report (IR) or a transcript (CT), and it is an initial announcement of results/milestones, 'ER' (Earnings Release) is the most appropriate classification among the provided options for a significant corporate update, even if it's not strictly tied to a quarterly earnings period. It is not a formal regulatory filing like a 10-K or a short RPA. Q1 2025
2025-02-28 English
Valneva reçoit un avis positif du CHMP de l’EMA pour élargir l’indication de son vaccin contre le chikungunya IXCHIQ® aux adolescents
Regulatory Filings Classification · 100% confidence The document is a press release dated February 28, 2025, announcing that Valneva received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to extend the indication of its chikungunya vaccine (IXCHIQ®) to adolescents aged 12 and older. This type of announcement, detailing regulatory milestones, clinical data updates, and strategic partnerships (like the one with CEPI and SII), is characteristic of a company communicating significant, timely business and scientific developments to the market. It is not a full Annual Report (10-K), an Audit Report (AR), a formal Dividend Notice (DIV), or a proxy statement (DEF 14A/PSI). It is a general corporate announcement regarding product development and regulatory progress. Since it is a press release announcing a major regulatory event (positive CHMP opinion), it fits best under the general category for significant corporate news that isn't strictly financial results (ER) or management changes (MANG). Given the options, this is a high-level corporate update, but it is not a specific financial filing like 10-K or IR. It is most closely aligned with an Earnings Release (ER) in terms of format (press release announcing key news), but the content is regulatory/product focused. However, since it is a formal announcement of a significant event that is not explicitly covered by other codes (like DIV, CAP, MANG, DIRS), and it is not a short notice about *attaching* a report (RPA/RNS), it functions as a primary corporate disclosure. In many databases, such detailed regulatory/product updates are often categorized as Earnings Releases if they are issued outside of standard quarterly reporting cycles, or sometimes as Regulatory Filings (RNS) if they are mandatory disclosures. Given the detailed nature and the focus on a major regulatory step, it is a significant corporate announcement. If we must choose from the provided list, and it's not a financial results release (ER), it functions as a general, important corporate update. Since it is a detailed press release about a regulatory milestone, it is not a simple 'Report Publication Announcement' (RPA). It is a primary disclosure. I will classify this as an Earnings Release (ER) as it functions as the primary vehicle for communicating material, non-financial operational news, which is a common practice for biotech/pharma companies when major regulatory news breaks outside of standard earnings cycles. Alternatively, RNS is a fallback. Given the high importance and structured nature, ER is a strong candidate, but RNS is the safest fallback for non-standard disclosures. Let's re-evaluate: It is not an earnings release (no financial results summary). It is a press release about a regulatory opinion. This is a material event disclosure. It is not a proxy, capital change, or director dealing. It is closest to a general regulatory announcement or a specific update. I will lean towards RNS as the most appropriate catch-all for significant, non-standard regulatory/product news that isn't explicitly defined elsewhere, although it is a very detailed press release.
2025-02-28 French
6-K
Regulatory Filings
2025-02-18 English
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
Earnings Release Classification · 100% confidence The document is a press release from Valneva SE titled 'Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook'. It provides key financial highlights, preliminary unaudited results, and forward-looking guidance for the upcoming year. It explicitly states that the final audited financial statements will be published at a later date (March 20, 2025). This fits the definition of an Earnings Release (ER), which is the initial announcement of periodic financial results containing key highlights. FY 2024
2025-02-18 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.